These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36490353)

  • 21. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
    Hu J; Wang T; Chen Q
    Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LINC00467 Is Upregulated by DNA Copy Number Amplification and Hypomethylation and Shows ceRNA Potential in Lung Adenocarcinoma.
    Wang W; Bo H; Liang Y; Li G
    Front Endocrinol (Lausanne); 2021; 12():802463. PubMed ID: 35095769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
    Wang L; Zhou SQ; Zhou Y; Lu JX
    J Immunol Res; 2022; 2022():8069858. PubMed ID: 35600050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative Analysis of Three Novel Competing Endogenous RNA Biomarkers with a Prognostic Value in Lung Adenocarcinoma.
    Tan J; Wang W; Song B; Song Y; Meng Z
    Biomed Res Int; 2020; 2020():2837906. PubMed ID: 32802839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
    Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
    Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
    Yu L; Qiao R; Xu J; Han B; Zhong R
    Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma.
    Sui J; Li YH; Zhang YQ; Li CY; Shen X; Yao WZ; Peng H; Hong WW; Yin LH; Pu YP; Liang GY
    Int J Oncol; 2016 Nov; 49(5):2023-2036. PubMed ID: 27826625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
    Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
    Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LARRPM restricts lung adenocarcinoma progression and M2 macrophage polarization through epigenetically regulating LINC00240 and CSF1.
    Li Y; Chen C; Liu HL; Zhang ZF; Wang CL
    Cell Mol Biol Lett; 2022 Oct; 27(1):91. PubMed ID: 36221069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 36. Six MicroRNA Prognostic Models for Overall Survival of Lung Adenocarcinoma.
    Li J; Gu X; Gao C; Zhang J
    Genet Res (Camb); 2022; 2022():5955052. PubMed ID: 36101742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.
    Luan T; Zhang TY; Lv ZH; Guan BX; Xu JY; Li J; Li MX; Hu SL
    FEBS Open Bio; 2021 May; 11(5):1504-1515. PubMed ID: 33683834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA MAFG-AS1 Promotes Lung Adenocarcinoma Cell Migration and Invasion by Targeting miR-3196 and Regulating SOX12 Expression.
    Wu Q; Jiang J
    Mol Biotechnol; 2022 Sep; 64(9):970-983. PubMed ID: 35275356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
    Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
    J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
    Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
    Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.